

**Director of Cytopathology
Moffitt Cancer Center**

Moffitt Cancer Center (MCC), an NCI-designated comprehensive cancer center in the state of Florida, and the #11 ranked Best Hospitals for Cancer on U.S. News & World Report, is seeking a leader who will serve as the Director of Cytopathology. The successful candidate will provide direction to an established and growing cytopathology service, during a time of significant growth and expansion at MCC.

The cytopathology team currently covers two sites, the MCC main campus and The Richard M. Schulze Family Foundation Outpatient Center/Moffitt's McKinley Campus (MKC). The MCC main campus is comprised of a large ambulatory care facility, a 206-bed hospital with a 36-bed blood and marrow transplant program, 20 state-of-the-art operating suites, a 30-bed intensive care unit, a high-volume screening program, and a basic science research facility. The Moffitt Research Institute located on the main campus is comprised of approximately 160 Principal Investigators, 58 laboratories, and 306,000 square feet of research space.

The Moffitt McKinley Campus was opened in 2015 and due to its success, there are plans for expansion already underway. MKC is a six-story, 207,000 square-foot facility located approximately one mile from MCC's main campus and provides a long list of patient care options ranging from skin cancer treatment to survivorship services to a breast cancer clinic and diagnostic imaging. In June 2020, MCC broke ground on a new \$400 million hospital to be located on the 20-acre McKinley Campus, which will be a 10-story, 498,000 square-foot facility, opened in order to expand MCC's capacity for inpatient hospital care. The new hospital is planned to open in July 2023. The first phase of the hospital will include 128 inpatient beds, 19 operating rooms, 72 perioperative rooms, three MRI scanners, three CT scanners and two nuclear cameras, radiology, endoscopy, imaging, conference space, and education and research space. The hospital will have the capacity to expand to 400 beds.

The incoming Director will be able to leverage existing strengths at MCC such as world-renowned oncologists, radiologists, basic scientists, epidemiologists and health outcomes researchers, and other top-rated scientists, all to further Moffitt's mission to prevent and cure cancer care. This position offers an exciting opportunity to build upon Moffitt's significant data and analytics assets, accelerating scientific discovery and translation to the clinic. Moffitt's size, its singular focus on cancer, and its close interaction and outreach with academic partners and caregivers throughout the state, nation, and world all contribute to the rich, collegial, and collaborative environment required to conduct outstanding translational cancer research and educate the next generation.

The successful candidate will have a track record of clinical and academic excellence with experience in high volume multidisciplinary university clinical settings. Candidates must have completed a subspecialty cytopathology fellowship, and expertise in another surgical pathology subspecialty is highly desirable but not required. Applicants must be board certified in Anatomic Pathology and Cytopathology. Licensure or eligibility for licensure in the State of Florida is required. Moffitt is committed to education through a wide range of residency and fellowship programs. The Department oversees an established, ACGME accredited Cytopathology Fellowship that accepts two fellows per year.

For inquiries please contact Jay Torio, Senior Director, Department of Academics at Merritt Hawkins: jay.torio@merritthawkins.com, or at 214-727-9505.